These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12106798)

  • 21. Sympathetic regulation of skeletal muscle blood flow in the pig: a non-adrenergic component likely to be mediated by neuropeptide Y.
    Modin A; Pernow J; Lundberg JM
    Acta Physiol Scand; 1993 May; 148(1):1-11. PubMed ID: 8333291
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-adrenergic, non-cholinergic vascular control with reference to neuropeptide Y, vasoactive intestinal polypeptide and nitric oxide.
    Modin A
    Acta Physiol Scand Suppl; 1994; 622():1-74. PubMed ID: 7524267
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuropeptide Y release and contractile properties: differences between canine veins and arteries.
    Hunter LW; Tyce GM; Rorie DK
    Eur J Pharmacol; 1996 Oct; 313(1-2):79-87. PubMed ID: 8905332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sympathetic control of skeletal muscle function: possible co-operation between noradrenaline and neuropeptide Y in rabbit jaw muscles.
    Grassi C; Deriu F; Roatta S; Santarelli R; Azzena GB; Passatore M
    Neurosci Lett; 1996 Jul; 212(3):204-8. PubMed ID: 8843108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of antihypertensive drugs on sympathetic vascular control in relation to neuropeptide Y.
    Lundberg JM; Pernow J; Franco-Cereceda A; Rudehill A
    J Cardiovasc Pharmacol; 1987; 10 Suppl 12():S51-68. PubMed ID: 2455193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuropeptide Y: an overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses.
    Heilig M; Widerlöv E
    Acta Psychiatr Scand; 1990 Aug; 82(2):95-114. PubMed ID: 2173355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of neuropeptide Y-induced augmentation of noradrenaline-induced vasoconstriction by D-myo-inositol 1,2,6-trisphosphate in the rat mesenteric arterial bed.
    Ralevic V; Edvinsson L; Burnstock G
    Acta Physiol Scand; 1994 Jul; 151(3):309-17. PubMed ID: 7976403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuropeptide Y receptor subtypes, Y1 and Y2.
    Wahlestedt C; Grundemar L; Håkanson R; Heilig M; Shen GH; Zukowska-Grojec Z; Reis DJ
    Ann N Y Acad Sci; 1990; 611():7-26. PubMed ID: 2174225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BIBP 3226, suramin and prazosin identify neuropeptide Y, adenosine 5'-triphosphate and noradrenaline as sympathetic cotransmitters in the rat arterial mesenteric bed.
    Donoso MV; Steiner M; Huidobro-Toro JP
    J Pharmacol Exp Ther; 1997 Aug; 282(2):691-8. PubMed ID: 9262332
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropeptide Y modulation of sympathetic activity in myocardial infarction.
    Basu S; Sinha SK; Shao Q; Ganguly PK; Dhalla NS
    J Am Coll Cardiol; 1996 Jun; 27(7):1796-803. PubMed ID: 8636570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The involvement of neuropeptide Y Y1 receptors in the blood pressure baroreflex: studies with BIBP 3226 and BIBO 3304.
    Capurro D; Huidobro-Toro JP
    Eur J Pharmacol; 1999 Jul; 376(3):251-5. PubMed ID: 10448884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.
    Antal-Zimanyi I; Bruce MA; Leboulluec KL; Iben LG; Mattson GK; McGovern RT; Hogan JB; Leahy CL; Flowers SC; Stanley JA; Ortiz AA; Poindexter GS
    Eur J Pharmacol; 2008 Aug; 590(1-3):224-32. PubMed ID: 18573246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GW1229, a novel neuropeptide Y Y1 receptor antagonist, inhibits the vasoconstrictor effect on neuropeptide Y in the hamster microcirculation.
    Bitran M; Daniels AJ; Boric MP
    Eur J Pharmacol; 1997 Jan; 319(1):43-7. PubMed ID: 9030896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuropeptide Y and cardiovascular regulation.
    Pedrazzini T; Brunner HR; Waeber B
    Curr Opin Nephrol Hypertens; 1993 Jan; 2(1):106-13. PubMed ID: 7922157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of sympathetic neurotransmission by neuropeptide Y Y2 receptors in rats and guinea pigs.
    Potter EK; Tripovic D
    Exp Brain Res; 2006 Aug; 173(2):346-52. PubMed ID: 16733694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropeptide Y is released from human mammary and radial vascular biopsies and is a functional modulator of sympathetic cotransmission.
    Donoso MV; Miranda R; Irarrázaval MJ; Huidobro-Toro JP
    J Vasc Res; 2004; 41(5):387-99. PubMed ID: 15377822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropeptide Y receptors as targets for anti-obesity drug development: perspective and current status.
    Parker E; Van Heek M; Stamford A
    Eur J Pharmacol; 2002 Apr; 440(2-3):173-87. PubMed ID: 12007534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of adenosine A2A and A3 receptors on the differential modulation of norepinephrine and neuropeptide Y release from peripheral sympathetic nerve terminals.
    Donoso MV; Aedo F; Huidobro-Toro JP
    J Neurochem; 2006 Mar; 96(6):1680-95. PubMed ID: 16539684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of neuropeptide Y and the sympathetic nervous system in vascular control in man.
    Clarke J; Benjamin N; Larkin S; Webb D; Maseri A; Davies G
    Circulation; 1991 Mar; 83(3):774-7. PubMed ID: 1999028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuropeptide Y: a new mediator linking sympathetic nerves, blood vessels and immune system?
    Zukowska Z; Pons J; Lee EW; Li L
    Can J Physiol Pharmacol; 2003 Feb; 81(2):89-94. PubMed ID: 12710520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.